Alnylam Pharmaceuticals ALNY Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| AMVUTTRA | $1.01B+106% | $889.93M+187% | $826.59M+189% | $685.3M+165% | $491.95M+114% | |
| GIVLAARI | $89.76M+11.0% | $74.39M+11.1% | $86.8M+34.3% | $73.87M+4.0% | $80.85M+30.1% | |
| ONPATTRO | $18.46M-64.9% | $20.48M-58.6% | $31.69M-43.5% | $39.08M-22.3% | $52.54M-32.0% | |
| OXLUMO | $52.12M+11.2% | $51.32M+21.9% | $49.65M+13.9% | $52.83M+31.4% | $46.87M+15.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Alnylam Pharmaceuticals break its business down?
- Alnylam Pharmaceuticals (ALNY) reports total revenues by product across 4 parts — AMVUTTRA, GIVLAARI, ONPATTRO and OXLUMO. Each is extracted from the segment footnotes and tracked over time.
- Where does Alnylam Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Alnylam Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
